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Mitotic chromatin condensation is essential for cell division in eukaryotes. Posttranslational modification of the
N-terminal tail of histone proteins, particularly by phosphorylation by mitotic histone kinases, may facilitate this
process. In mammals, aurora B is believed to be the mitotic histone H3 Ser10 kinase; however, it is not sufficient
to phosphorylate H3 Ser10 with aurora B alone. We show that histone H3 is phosphorylated by vaccinia-related
kinase 1 (VRK1). Direct phosphorylation of Thr3 and Ser10 in H3 by VRK1 both in vitro and in vivo was observed.
Loss of VRK1 activity was associated with a marked decrease in H3 phosphorylation during mitosis. Phosphory-
lation of Ser10 by VRK1 is similar to that by aurora B. Moreover, expression and chromatin localization of VRK1
depended on the cell cycle phase. Overexpression of VRK1 resulted in a dramatic condensation of nuclei. Our
findings collectively support a role of VRK1 as a novel mitotic histone H3 kinase in mammals.
Chromatin congregates to chromosomes during mitosis to fa-
cilitate the even segregation of genetic information to two daugh-
ter cells. In nucleosomes, the combinational modification of
histone tails, the so-called “histone code,” controls chromatin-
templated processes from gene expression to cell fate decision
(20, 30). Phosphorylation of the N-terminal tail of histone H3 may
be responsible for chromatin condensation (21). During mitosis,
the N-terminal tail of histone H3 is phosphorylated at several
residues, including Thr3 (5, 36), Ser10 (3, 7, 17, 18), Thr11 (37),
and Ser28 (12). A correlation between histone H3 Ser10 phos-
phorylation and chromatin condensation in Aspergillus nidulans
(6) and Tetrahymena thermophila (47) is well established. How-
ever, in other species, condensation is not accomplished simply by
Ser10 phosphorylation, and additional phosphorylation or modi-
fication of histone tails is required (21).
A number of studies have shown that members of the aurora
kinase family are responsible for phosphorylation of histone H3
(3, 7, 17, 18). Mammals contain three isotypes of aurora kinase
designated aurora A, B, and C (11). Among these, aurora B is a
strong candidate phosphorylator of Ser10 in histone H3 as is
evident from data obtained with hesperadin, the aurora B inhib-
itor (14), which suppressed Ser10 phosphorylation during mitosis
(7, 17). However, residual Ser10 phosphorylation was detected,
even upon depletion of aurora B in cells, suggesting the presence
of an additional histone H3 kinase (29).
NIMA (never in mitosis), the histone H3 Ser10 kinase in
Aspergillus nidulans (6, 34), triggers chromatin condensation in
cells arrested at the interphase (28). In mammals, Nercc1, the
functional ortholog of NIMA, was found to be phosphorylating
histone H3 (39). Nucleosomal histone kinase 1 (NHK1) from
Drosophila melanogaster is the kinase shown to phosphorylate
histone protein in chromatin as a substrate. NHK1 phosphor-
ylated H2A at Thr119 in chromatin but not with free histone as
the substrate (1). Recent studies showed that NHK1 partici-
pates in mitotic progression (4) and maintenance of proper
chromosomal architecture (19). These data strongly indicate
that NHK1 is a bona fide mitotic histone kinase.
Vaccinia-related kinase 1 (VRK1) is the mammalian ho-
molog of NHK1 (1). Sequence similarities between NHK1 and
VRK1 are evident in the kinase domain (approximately 40%
identity), and the carboxyl termini contain a characteristic
basic-acidic-basic motif (1). VRK1, identified from the screen-
ing of novel genes involved in cell cycle regulation from fetal
liver (31), is designated on the basis of 40% sequence identity
with vaccinia virus B1 kinase, which plays a critical role in viral
DNA replication (38). The kinase is highly expressed in pro-
liferative tissues, including embryonic tissues, adult testis, and
thymus, as well as in several cancer cell lines, implying a func-
tional role in cell cycle regulation and tumorigenicity (31).
VRK1 participates in cell cycle progression by means of phos-
phorylation of a barrier-to-autointegration factor (BAF) that
plays structural roles in chromatin and the nuclear envelope
and displays subcellular localization changes during the cell
cycle (33) and by activating the transcription of proliferation-
related proteins such as retinoblastoma, cyclin-dependent ki-
nase 2, and survivin (40).
In this report, we demonstrate that VRK1 is a chromatin-
associated protein displaying cell cycle-dependent expression and
subcellular localization. VRK1 phosphorylates Thr3 and Ser10 in
free and core histone H3 and in nucleosomes. Overexpression of
the constitutively active form of VRK1 leads to hypercondensa-
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tion of the nucleus, in similarity to data obtained in studies of
NIMA, the fungal enzyme, in eukaryotic cells.
MATERIALS AND METHODS
Plasmids and antibodies. To generate VRK1 expression constructs, mouse,
rat, and human full-length VRK1 was amplified by PCR from a day-16 mouse
embryo cDNA library (Clontech), from Rat-1 cell cDNA, and from HeLa cell
cDNA, respectively. For mammalian expression constructs, VRK1 and its kinase-
dead mutant generated by site-directed mutation (Lys179 to Glu) were sub-
cloned into pcDNA3.1 (Invitrogen), pFlag-CMV2 (Sigma), and pEGFP-N1,
pEGFP-C1, pDsRed1-N1, and pDsRed1-C1 (BD Biosciences). Human VRK3
and HP1 cDNAs were subcloned into pDsRed1-C1 and pEGFP-N1, respec-
tively. For expression in Escherichia coli, VRK1 and its mutants (VRK2, VRK3,
and histone H3 mutants) were subcloned into pPosKJ, pProEX, or pGEX-4T-1
(Amersham) as described previously (25). VRK antisera were prepared as de-
scribed previously (23). The following antibodies were purchased from commer-
cial sources: anti-Flag epitope (M2) from Sigma; anti-green fluorescent protein
(anti-GFP; C163) from Zymed; anti-glyceraldehyde 3-phosphate dehydrogenase
(anti-GAPDH) and antibromodeoxyuridine (anti-BrdU) from Calbiochem; anti-
phospho-cdc2 (Tyr15) and anti-cleaved caspase3 from Cell Signaling Technol-
ogy; anti-RNA polymerase II from Abcam; anti-DsRed1 and anti-aurora B
(AIM-1) from BD Biosciences; anti-lamin B, anti--tubulin, anti-cyclin D1, anti-
GFP, and anti--tubulin from Santa Cruz Biotechnology; and all antihistone
antibodies used in this study as well as anti-HP1 from Upstate Biotechnology.
Extraction of subcellular fractions. Cytoplasmic and nucleoplasmic extracts
were prepared as described previously (23). The pellet obtained following the
extraction of the nucleoplasm, which contained the subnuclear organelles and
chromatins, was further extracted as follows. A euchromatin-enriched fraction
was isolated as the soluble fraction following treatment of the pellet with DNase
I for 1 h at room temperature. Next, the pellet remaining after the euchromatin
extraction was vigorously sonicated to obtain the nuclear matrix. Finally, follow-
ing the nuclear matrix extraction, the pellet was treated with 6 M urea and 2%
sodium dodecyl sulfate to solubilize the heterochromatin-enriched fraction. To
prepare crude soluble chromatin, the pellet from the nucleoplasmic extraction
was treated with micrococcal nuclease (100 U) for 1 h at 30°C. Each fraction was
evaluated by Ponceau S staining and immunoblotting.
Immunoprecipitation, immunoblotting and immunocytochemistry. Immuno-
precipitation, immunoblotting, and immunocytochemistry were performed as
described previously (23).
TUNEL assay. For the TUNEL (terminal deoxynucleotidyltransferase-medi-
ated dUTP-biotin nick end labeling) assay, HeLa cells transfected with DsRed1-
C1-VRK1 for various time periods were grown on glass chips coated with poly-
D-lysine (Sigma). Cells were then fixed with 4% paraformaldehyde, the glass
chips were removed, and the cells were permeabilized and stained with a Dead-
End fluorometric TUNEL system kit (Promega) according to the manufacturer’s
instructions.
Protein kinase assay. An in vitro kinase assay was performed with 100 ng (see
Fig. 4E, G, and H) to 1 g (see Fig. 4B to D and F) of either recombinant
glutathione S-transferase-VRK1 (GST-VRK1) or VRK1 protein and 100 ng (see
Fig. 4E, G, and H) or 1 g (see Fig. 4B to D and F) of substrates, including core
histones, nucleosomes, each histone protein, and BAF. The duration of the
kinase assay was 30 min except for that of one assay (see Fig. 4H). The standard
procedure for the in vitro kinase assay was carried out as described previously
(23). The kinase activity of VRK1 in cell extracts was analyzed using immuno-
precipitated VRK1 with anti-VRK1 antibody.
Cell culture and transfection. HeLa and H1299 cells were grown in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 100 U/ml of both penicillin G and streptomycin. Transient transfec-
tion of HeLa and H1299 cells was carried out using Metafectene reagent (Bion-
tex, Munich, Germany) according to the manufacturer’s protocol. For immuno-
cytochemical analysis, cells were grown on a glass chip coated with poly-D-lysine.
Transfected cells were maintained or treated with drugs for appropriate times
before microscopic observation. The small interfering RNA (siRNA) duplex
targeting human VRK1 (siVRK1 combined with two siRNA duplexes, GCTAA
GCTTAAGAATTCTG and CAAGGAACCTGGTGTTGAA) and targeting
human aurora B (siAurB; catalog no. L-003326-00) and the control scrambled
siRNA (siCont) were obtained from Dharmacon (Lafayette, CO).
Cell cycle synchronization and flow cytometry. HeLa cells were synchronized
as described previously (26). Briefly, cells were arrested in mitotic phase by
treatment for 12 h with 10 nM taxol (Paclitaxel; Sigma) and 0.4 g/ml nocodazole
(Sigma), in G1 by treatment for 24 h with 2 mM hydroxyurea, and in G1/S by
treatment for 20 h with 200 M mimosine. A double thymidine blocking was
performed as described previously (16). Briefly, cells were treated with 2 mM
thymidine for 20 h, released for 6 h in fresh DMEM containing 10% FBS, and
treated again with 2 mM thymidine for 12 h. Cells arrested in G1/S were released
by switching the medium to fresh DMEM containing 10% FBS. Aliquots were
analyzed by flow cytometry, and the remaining cells were used for the prepara-
tion of whole-cell extracts or subcellular fractions. For flow cytometric analysis,
the cells were fixed with 70% ethanol for 20 min, stained with 20 g/ml pro-
pidium iodide, and treated with 1 g/ml RNase A for 10 min at room temper-
ature. Samples containing 10,000 cells were then analyzed on a FACSCalibur
system (Becton Dickinson).
Purification of recombinant proteins and GST pulldown assay. Monomeric
BAF protein was prepared from the insoluble fraction by tobacco etch virus
protease treatment to cleave the hexameric His tag as described previously (33).
The purification of GST fusion proteins and the GST pulldown assay were
carried out as described previously (23, 25).
Semiquantitative RT-PCR. Total RNA was isolated using TRI reagent (Mo-
lecular Research Center) according to the manufacturer’s instructions. Reverse
transcription-PCR (RT-PCR) was carried out as described previously (22).
Briefly, following DNase I (Promega) treatment, RNA was reverse transcribed
using oligo(dT) (Promega) and monkey murine leukemia virus reverse transcrip-
tase (Roche) in the presence of RNasin (Promega). To obtain semiquantitative
results, primers for both GAPDH and VRK1 were included in each reaction
mixture.
RESULTS
Cell cycle-regulated expression of VRK1. We monitored
VRK1 expression during cell cycle progression by use of a
VRK1-specific antibody which only recognized VRK1 in vari-
ous experiments, including immunoblotting, immunoprecipita-
tion, and immunocytochemistry (see Fig. S1 in the supplemen-
tal material). Mitotic arrest induced by treatment with
nocodazole or taxol elevated the VRK1 protein (Fig. 1A) and
mRNA (Fig. 1C) levels. In contrast, cells arrested at the G1 or
S phase by treatment with hydroxyurea or mimosine, respec-
tively, showed decreased or moderately elevated VRK1 ex-
pression compared to asynchronous control cells (Fig. 1A and
C). The increase in VRK1 expression during mitosis was fur-
ther confirmed using a washout study. Nocodazole washout
triggered the transition of synchronized cells from mitotic
phase to G1 phase accompanied by a decrease in VRK1 ex-
pression (Fig. 1D). Nuclear localization of VRK1 was con-
firmed by immunostaining with an anti-VRK1 antibody (Fig.
1E). Unexpectedly, the endogenous VRK1 content differed
among cells at different phases of the cycle (Fig. 1E). Specifi-
cally, in mitosis, intense VRK1 staining at the prophase was
observed which gradually decreased and was barely detectable
from the anaphase to the telophase (Fig. 1F). To determine
the cellular expression of VRK1 in asynchronously growing
HeLa, cells in the S phase were labeled with BrdU for 1 h. We
additionally applied Hoechst staining to identify cells at the G1
(relatively weak staining) or G2 (relatively intense staining)
phase. Cells in the M phase were identified according to their
unique chromosomal shape following Hoechst staining. Thus,
the cell cycle stages for individual cells were determined using
a combination of Hoechst staining and BrdU labeling (see Fig.
1I for a cell cycle chart based on staining patterns). This
method disclosed clear differences in the cellular content of
VRK1 according to the cell cycle stage. At G1, VRK1 was
barely detectable, but it gradually accumulated from the S to
G2 phase in both HeLa (Fig. 1G) and H1299 (Fig. 1H) cells.
Based on these results, we conclude that VRK1 is differentially
expressed during cell cycle progression and peaks in the G2/M
phase.
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Chromatin localization of VRK1. VRK1 is a nuclear protein
(27, 32). To determine its subnuclear localization, nuclei were
biochemically fractionated. Both endogenous VRK1 (Fig. 2A)
and Flag-tagged VRK1 (Fig. 2B) were predominantly located
in the nucleoplasm; a substantial amount of VRK1 was iden-
tified in the chromatin-enriched fractions (Fig. 2A and B).
Chromatin localization of VRK1 was further confirmed by
immunocytochemical analysis. A high VRK1 level was ob-
FIG. 1. Profile of VRK1 expression during cell cycle progression. (A to C) Differential expression of VRK1 during cell cycle progression. Total extracts were
prepared from asynchronously growing HeLa cells (Async. [control]) or cells treated with taxol and nocodazole (Noco.) for mitotic arrest or hydroxyurea (HU)
and mimosine (Mimo) for G1/S arrest. The extracts were analyzed by immunoblotting with the indicated antibodies (A). Cell cycle synchronization was validated
by flow cytometric analyses (B). The level of VRK1 transcript during each phase of the cell cycle was measured by semiquantitative RT-PCR (C). (D) VRK1
protein levels from asynchronously growing HeLa cells following a 12-h treatment with nocodazole and then a 1-h washout with fresh medium. (E) Immuno-
staining for VRK1 (green) and DNA (Hoechst; blue) in HeLa cells transfected with DsRed1-C1-VRK1. The arrow indicates a transfected cell, and arrowheads
indicate nontransfected cells with a high level of endogenous VRK1 expression. (F) Immunostaining for VRK1 (green) and DNA staining (propidium iodide
[PI]; red) during interphase and mitosis. Pro, prophase; Prometa, prometaphase; Meta, metaphase; Ana, anaphase; Telo, telophase. (G and H) Immunostaining
for S-phase cells (BrdU-positive; green), VRK1 (red), and DNA staining (Hoechst; blue) in HeLa (G) or H1299 (H) cells. The stages of the cell cycle are
indicated in yellow and were evaluated according to the criteria presented in panel I. (I) Chart to evaluate the stage of the cell cycle according to BrdU and
Hoechst staining results. The scale bars in panels E to H represent 10 m.
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FIG. 2. Subnuclear localization of VRK1 protein. (A and B) Fractions from untransfected cells (A) or pFlag-VRK1-transfected cells (B) were
analyzed by immunoblotting with the indicated antibodies. Antibodies against GAPDH, phospho-cdc2 (p-cdc2), RNA polymerase II (RNAP II), lamin
B, and histone H3 (H3) were used as markers for the various fractions. (C) Immunostaining for VRK1 staining (green) and DNA staining (Hoechst;
blue). Arrows indicate cells in interphase (nuclear envelope present), and arrowheads indicate mitotic cells (nuclear envelope absent). DIC, differential
interference contrast. (D) Expression of Flag-VRK1 and its accumulation in chromatin during the cell cycle. HeLa cells were cotransfected with pFlag-VRK1
and pEGFP-N1 for 12 h, and then cell cycle was arrested at G1/S phase induced by hydroxyurea (HU) and mitotic phase induced by nocodazole (Noco.).
Subcellular fractions were prepared as described in Materials and Methods. Ponceau S staining of the blot shows the quantity and quality of the fractions. It is
notable that there is no nucleoplasm in mitotic cells (Noco. treated); the label nucleoplasm was used here for convenience to indicate the biochemical preparation
for the asynchronous (Async.) control and G1/S-arrested cells. (E) Colocalization of VRK1 and HP1. Cells were cotransfected with pFlag-VRK1 (upper panel)
and pEGFP-HP1 and then stained for Flag (red; upper panel) and DNA (Hoechst; blue). Scale bars in panels C and E represent 10 m.
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served in the area of dense chromosomes, even in cells lacking
a nuclear envelope (Fig. 2C). Cell cycle synchronization by
drug treatment after transient expression of Flag-VRK1 fur-
ther confirmed subcellular localization. The Flag-VRK1 level
varied depending on the stage of cell cycle arrest (Fig. 2D).
Compared to control asynchronous cell results, the VRK1 pro-
tein level was lower in G1/S and higher in mitotic phase (Fig.
2D). Interestingly, the chromatin-localized VRK1 level was
higher in mitotic arrested cells than in asynchronously growing
or G1/S-arrested cells (Fig. 2D). Moreover, VRK1 colocalized
with gamma heterochromatin protein 1 (HP1) (Fig. 2E), a
well-known chromatin-associated protein (15), which is consis-
tent with results from a previous proteomic analysis showing
VRK1 to be a chromatin-associated protein (45). Similarly,
affinity chromatography with the DNA fragment of Cyp2b10,
the phenobarbital-inducible p450 gene, was applied to identify
VRK1 (48). The data strongly suggest that VRK1 is localized
not only in nucleoplasm but also in chromatin.
Association of VRK1 and core histones. To investigate the
significance of VRK1 association with chromatin, we isolated
VRK1-binding proteins from soluble chromatin extracts. A
GST pulldown assay led to the identification of four bands
ranging from 14 to 17 kDa (Fig. 3A, middle panel). Matrix-
assisted laser desorption ionization–time of flight (tandem
FIG. 3. Association and colocalization of VRK1 and core histones in chromatin. (A) Identification of core histones as binding partners of VRK1. VRK1
binding proteins were identified in the nucleoplasm and solubilized chromatin fractions by use of a GST pulldown assay. Left panel, Coomassie brilliant blue
(CBB)-stained gel containing total extract from each fraction and GST or GST-VRK1; middle panel, CBB-stained gel after pulldown using GST or GST-VRK1.
Core histones were identified by MALDI-TOF MS/MS, and the peptide sequences are presented in the right panel. (B) Immunoblotting (IB) results for H3 and
H2B. The gel shown in the middle of panel A was transferred to a nitrocellulose membrane and analyzed by immunoblotting with antibodies against histones
H3 and H2B. (C) Direct binding of VRK1 and core histone proteins. Purified free core histones were pulled down with GST or GST-VRK1. (D) Colocalization
of VRK1 and H3. HeLa cells were stained for VRK1 (red), histone H3 (green), and nuclei (Hoechst; blue). Bar, 5 m.
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mass spectrometry) (MALDI-TOF MS/MS) analyses revealed
that three of these proteins were core histones H2B, H3, and
H4 (Fig. 3A, right panel). Immunoblotting of the gel (shown in
the middle panel in Fig. 3A) confirmed interactions of histone
H3 and H2B with VRK1 (Fig. 3B). Pulldown assays using GST
(control) or GST-VRK1, followed by immunoblotting for H3
and H2B, disclosed direct binding (Fig. 3C). Immunocyto-
chemistry analyses further supported the colocalization of
VRK1 and H3 (Fig. 3D). Since histones are basic proteins and
VRK1 autophosphorylates at several sites as well (27), we
examined whether autophosphorylation is required for histone
binding. Dominant-negative and kinase-dead mutants of
VRK1 generated by deletion of a partial ATP-binding site
(amino acids 43 to 49) of wild-type VRK1 and by point muta-
tion of Lys179 to Glu, respectively, still bound H3 (see Fig. S2
in the supplemental material), indicating that VRK1 autophos-
phorylation is not necessary for H3 binding or colocalization
with core histones in chromatin.
Phosphorylation of H3 by VRK1 in vitro. NHK-1 phosphor-
ylates histones in the context of chromatin (1). Our binding
data showing interaction between VRK1 and core histones
(Fig. 3), as well as sequence and structural similarities between
VRK1 and NHK1 (1), suggest that VRK1 phosphorylates hi-
stone proteins. To examine this possibility, we performed an in
vitro kinase assay using free core histones as substrates. The
upper band observed with free histone H3 or H2B was a
VRK1-phosphorylated form (Fig. 4A). To confirm the rele-
vance of these results, we examined the phosphorylation of
pure histone proteins. VRK1 phosphorylated H3 strongly and
H2A, H2B, and H4 weakly and did not phosphorylate H1 (Fig.
4B). In contrast, NHK1 phosphorylated histone proteins only
when present in the nucleosome (1). Thus, VRK1 displays
histone kinase activity, but its specificity is somewhat different
from that of NHK1. The N-terminal tail of H3 is phosphory-
lated at several sites, including Thr3 by haspin (5), Ser10 and
Ser28 by aurora B (3, 12, 18), and Thr11 by Dlk/ZIP kinase
(37). To identify the VRK1 phosphorylation sites on histone
H3, we conducted an in vitro kinase assay and analyzed the
phosphorylated protein by immunoblotting with site-specific
anti-phospho-H3 antibodies. VRK1 phosphorylated purified
histone H3 at two sites, specifically, Thr3 and Ser10 (Fig. 4C).
Phosphorylation at these sites was additionally observed in
purified free core histones (Fig. 4C) and monomeric nucleo-
somes (Fig. 4D). To exclude other phosphorylation sites, we
generated site-directed mutants of H3 designated T3A, S10A,
and T3A/S10A. VRK1 phosphorylated T3A or S10A at the
nonmutated site but could not phosphorylate the T3A/S10A
mutant, which contained substitutions at both sites (Fig. 4E).
Our results indicate that VRK1 phosphorylates H3 at both
Thr3 and Ser10.
Finally, a dominant-negative mutant of VRK1 eliminated
Ser10 phosphorylation (Fig. 4F), confirming that this process is
mediated by VRK1. It is known that VRK1 phosphorylates
BAF (33). Thus, we compared VRK1-mediated protein phos-
phorylation results using BAF and histone H3. The phosphor-
ylation patterns of BAF and histone H3 were similar, and the
intensity was in proportion to VRK1 concentration (Fig. 4G)
and incubation duration (Fig. 4H), although phosphorylation
of greater intensity was found when monomeric BAF was used
as a substrate (Fig. 4G and H). We thought that one of the
reasons that BAF showed stronger phosphorylation than his-
tone H3 during the in vitro kinase assay might be the difference
in the number of residues phosphorylated by VRK1. VRK1
phosphorylates at three different residues of BAF with identi-
cal levels of potency (33), while VRK1 phosphorylates at Thr3
similarly strongly but phosphorylates Ser10 at the weaker level
seen with histone H3 in vitro.
Phosphorylation of H3 by VRK1 in vivo. To establish
whether VRK1 kinase is required for histone H3 phosphory-
lation in vivo, we examined the effects of overexpressing Flag-
VRK1 or knocking down VRK1 expression by use of siRNA.
Overexpression of wild-type VRK1 increased the level of the
mitotic index protein -tubulin approximately fivefold in com-
parison to the results seen with the vector control or the ki-
nase-dead mutant of VRK1 (Fig. 5A) as well as the level of H3
phosphorylation at both Thr3 and Ser10 in the heterochroma-
tin-enriched fraction (Fig. 5B). Consistently, knockdown of
endogenous VRK1 by siRNA reduced phosphorylation of H3
at both Thr3 and Ser10 (Fig. 5C). Ser10 but not Thr3 phos-
phorylation can be confirmed indirectly, as previous studies
showed that HP1 binding to chromatin and H3 phosphoryla-
tion at Ser10 are mutually exclusive (41). HP1 is loaded on
chromatin via binding to triple-methylated Lys9 of H3 (8),
which suppresses Ser10 phosphorylation. However, when
Ser10 is phosphorylated first, HP1 binding to chromatin is
inhibited (7, 17).
In accordance with the theory of mutually exclusive binding,
overexpression or knockdown of VRK1 altered the association
of HP1 in chromatin fractions (Fig. 5D). By examining chro-
matin-loaded HP1, we could indirectly verify VRK1-medi-
ated Ser10 phosphorylation of H3. Since aurora B is a known
histone H3 kinase during mitosis (3, 18), we examined its
relationship with VRK1 with regard to H3 phosphorylation at
Ser10. HeLa cells transfected with siRNAs indicated in Fig. 5E
FIG. 4. Phosphorylation of Thr3 and Ser10 in H3 by VRK1 in vitro. (A and B) Phosphorylation of H3 from purified free core histones (A) or
individual histone proteins (B) by VRK1. “32P” indicates the autoradiogram results. (C and D) Identification of sites in H3 phosphorylated by
VRK1. Following an in vitro kinase assay (IVK), purified core histone proteins (panel C, left half), purified H3 protein (C, right half), and
nucleosomes (D) from HeLa cells were analyzed by immunoblotting (IB) with site-specific anti-phosphorylated histone antibodies. Agarose gel
electrophoresis followed by ethidium bromide (EtBr) staining confirmed the presence of monomeric nucleosomes containing DNA (panel D,
bottom). (E) Confirmation of phosphorylation sites of histone H3 by VRK1 by use of either wild-type (WT) or mutated histone H3. (F) Re-
quirement of VRK1 activity for H3 phosphorylation. Addition of dominant-negative VRK1 (DN-VRK1) reduced the phosphorylation of histone
H3 Ser10 by wild-type VRK in vitro. (G and H) Phosphorylation results for monomeric BAF (mBAF) and histone H3 as substrates were compared
in different concentrations of VRK1 (G) and for various time periods of incubation (H). Bars and error bars represent means standard deviations
(n  3) (G and H). In all panels, the quantity of loaded sample was visualized by staining with Coomassie brilliant blue (CBB). VRK1 lacking a
GST moiety was used in panels B, E, and F.
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for 24 h were further grown in the culture media for 12 h in the
presence of nocodazole to be arrested at the mitotic prometa-
phase. Cells on the mitotic phase were collected by a shaking-
off method. Expectedly, depletion of VRK1 resulted in the
reduction of phosphorylation at both Thr3 and Ser10 in his-
tone H3 but not at Thr11 and Ser28, whereas depletion of
aurora B resulted in the reduction of phosphorylation at both
Ser10 and Ser28 but not at Thr3 and Thr11 (Fig. 5E). Inter-
estingly, both aurora B and VRK1 were required for phos-
phorylation of Ser10. Furthermore, a double knockdown of the
two genes dramatically reduced Ser10 phosphorylation (Fig.
5E). When we treated siVRK1, we observed a dramatic de-
crease in histone H3 Thr3 and Ser10 phosphorylation even
though the cells were synchronized at prometaphase in the
presence of nocodazole (Fig. 5F). Phosphorylation of histone
H3 on Thr3 is very prominent at the prometaphase in HeLa
cells (5). The incomplete knockdown of histone H3 phos-
phorylation shown in Fig. 5F might have been due to the action
of other mitotic histone kinases, such as haspin and aurora B,
that can phosphorylate Thr3 and Ser10, respectively. VRK1
expression and H3 phosphorylation at Thr3 and Ser10 coin-
cided in mitotic cells. Specifically, during the prophase, VRK1
and phosphorylated H3 colocalized throughout the nucleus,
and during prometaphase, VRK1 was delocalized from a more
restricted area containing a high level of phosphorylated H3
(Fig. 5G). To measure the intrinsic activity of VRK1 during the
cell cycle, we used immunoprecipitated VRK1, which was val-
idated to check the phosphorylation at Thr3 but not at Thr11
of histone H3 (Fig. 5H). VRK1 kinase activity and expression
were increased at late G2 or early M phase (Fig. 5I). The
results collectively suggest that VRK1 is a key mediator of
phosphorylation of histone H3 at Thr3 and Ser10 in vivo.
Hyperphosphorylation of histone H3 by a hyperactive form
of VRK1. Among the tagged (including His, Flag, enhanced
GFP, and DsRed1) VRK1 constructs, VRK1 fused to the C
terminus of DsRed1 (DsRed1-C1-VRK1) displayed the stron-
gest kinase activity (Fig. 6A) and highest protein level (Fig.
6B). While Flag-VRK1 was localized in chromatin of mitotic
cells (Fig. 2D), DsRed1-C1-VRK1, which was highly expressed
in chromatin, bypassed cell cycle stages determined by the
levels of marker proteins such as cyclin D1 for G1/S phase and
-tubulin for mitotic phase and led to the hyperphosphoryla-
tion of Thr3 and Ser10 in histone H3 (Fig. 6C) compared to
Flag-VRK1 results (Fig. 2D). The mechanism underlying the
strong kinase activity of DsRed1-C1-VRK1 is unclear at
present and requires further structural analysis. During an in
vitro kinase assay, both purified GST-VRK1 and immunopre-
cipitated-DsRed-VRK1 phosphorylated core histone as a sub-
strate (Fig. 6D, left panel). However, upon the incubation with
total cell extracts, while the activity of DsRed-VRK1 was re-
duced only 1.4-fold, that of GST-VRK1 was reduced more
than 10-fold (Fig. 6D, right panel). Accordingly, we speculated
that a strong inhibitory factor in total cell extracts may sup-
press VRK1 activity. To determine where this inhibition occurs
in cells, we fractionated cell extracts into cytoplasmic, nucleo-
plasmic, and crude chromatin fractions followed by incubation
with VRK1 to analyze its activity. Inhibition of VRK1 was
evident upon incubation with the nucleoplasm fraction (Fig.
6E). However, we could not identify the inhibitory binding
partner in nucleoplasm. The data collectively suggest that
DsRed1-C1-VRK1 is a constitutively active form of VRK1 and
is not affected by an unidentified nuclear inhibitor that strongly
suppresses VRK1 activity and hence shows extraordinarily
stronger kinase activity than any other tag-fused VRK1 pro-
teins.
Nuclear condensation by overexpressed VRK1. Never-in-
mitosis in Aspergillus nidulans (NIMA) histone H3 Ser10 ki-
nase is the single protein known to date that induces shrinkage
of the nucleus when ectopically overexpressed in mammalian
cells (28). In our experiments, transfection of cells with
DsRed1-C1-VRK1 led to dramatic nuclear condensation (Fig.
7A) similar to that observed in transient expression of NIMA,
the fungal enzyme, in eukaryotic cells (28). In addition, cells
transfected with DsRed1-C1-VRK1 displayed significantly
FIG. 5. Phosphorylation of Thr3 and Ser10 in H3 by VRK1 in vivo. (A) Increase of the mitotic index (-tubulin) after transient expression of
VRK1. Total extracts from HeLa cells transfected with vector (pFlag), Flag-VRK1, or Flag-tagged kinase-dead VRK1 (KD-VRK1) were analyzed
by immunoblotting (IB) with the indicated antibodies. The mitotic index was determined from the level of -tubulin. (B) Increased phosphorylation
of histone H3 at Thr3 and Ser10 in heterochromatin induced by overexpression of VRK1. Subcellular fractions from HeLa cells transfected with
either Flag-VRK1 or vector alone were analyzed by immunoblotting. (C) Reduction of phosphorylation of Thr3 and Ser10 in H3 by knockdown
of VRK1 by use of siRNA. HeLa cells transfected with siControl or siVRK1 were treated with nocodazole (Noco.) for 12 h to enhance the basal
level of phospho-Thr3 and phospho-Ser10. (D) Regulation of the localization of HP1 in chromatin by VRK1. Overexpression of VRK1 decreases
the level of HP1 in the chromatin fraction, whereas knockdown of VRK1 increases it. (E) VRK1 and aurora B independently phosphorylate Ser10
of H3. HeLa cells transfected with siControl, siVRK1, siAurB, and both siVRK1 and siAurB were treated with nocodazole for 12 h to enhance the
basal level of phospho-Ser10. Cells on the mitotic phase were collected by shaking-off method, and then total extracts from each transfected cells
were analyzed by immunoblotting with the indicated antibodies. Representative results from three independent experiments are presented.
(F) HeLa cells transfected with siControl and siVRK1 for 24 h were further treated with nocodazole for 12 h. Cells on the mitotic phase were
observed using fluorescence microscopy. Cells were stained for VRK1 (red), phospho-histone H3 (green), and nuclei (Hoechst; blue). DIC,
differential interference contrast. Scale bar, 5 m. (G) Colocalization of phospho-Thr3 and phospho-Ser10 with VRK1 in early mitotic cells.
Immunostaining for VRK1 (green), phospho-H3 Thr3, or phospho-H3 Ser10 (red) and DNA (Hoechst; blue). Arrowheads indicate highly
phosphorylated regions in the DNA. Scale bar, 5 m. pro, prophase; pro-meta, prometaphase. (H) Control experiment for the validation of in vitro
kinase assay using immunoprecipitated (IP) VRK1. Immunoprecipitated VRK1 prepared from control or pFlag-VRK1-transfected cells were used
in the in vitro kinase assay with wild-type or mutated histones as substrates. The VRK1 kinase activity was assessed by immunoblotting with an
anti-phospho-Thr3 antibodies. (I) Endogenous VRK1 kinase activity during the cell cycle. HeLa cells were manipulated in the cell cycle by
treatment with nocodazole (Noco.; for mitotic arrest) or by double thymidine blocking (0 h for S arrest; 4 h for G2 arrest; 8 and 10 h for mitotic
arrest). VRK1 was immunoprecipitated and used in an in vitro kinase (IVK) assay with free core histones as substrates (upper panel). Coomassie
brilliant blue (CBB) staining shows the quantity of substrate in each reaction. The stage of the cell cycle was validated by immunoblotting using
anti-phosphorylated histone antibodies. Async., asynchronous.
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more condensed nuclear shrinkage than control (DsRed1-C1-
transfected) cells and those transfected with DsRed1-C1-
VRK3 (Fig. 7B). Condensed nuclei were classified into three
types according to morphology, specifically, heterochromati-
nized foci (Fig. 7Ci), uniform comprehensive condensation
(Fig. 7Cii), and partitioned comprehensive condensation (Fig.
7Ciii). A percentage of the three classification types are shown
in Fig. 7C. The highest levels of uniform and partitioned com-
prehensive condensation occurred in G1 and G2/S cells, respec-
tively (Fig. 7D). Partially condensed foci were detected from
FIG. 6. DsRed1-C1-VRK1 is a constitutively active form of VRK1. (A) In vitro kinase assay (IVK) of immunoprecipitated VRK1 (VRK1-IP)
from cells transfected with various VRK1-expressing vectors. DsRed1-C1-tagged VRK1 displayed the strongest kinase activity. Purified core
histones were used as the substrate. Coomassie brilliant blue (CBB) staining was used to estimate the substrate amounts. (B) Immunoblot of
anti-VRK1 from total cell extracts of each VRK1-expressing sample. (C) Subcellular distribution and expression of DsRed1-C1-VRK1 in
asynchronously growing, G1/S arrest induced by hydroxyurea (HU) and mitotic arrest induced by nocodazole (Noco.) cells. Cells asynchronously
growing (Async.; control) cotransfected with DsRed1-C1-VRK1 and enhanced GFP-N1 were fractionated as described in Materials and Methods.
The levels of cyclin D1 and -tubulin were used as cell cycle markers for the G1/S and mitotic phases, respectively. (D) Preincubation of VRK1
with total cell extracts reduced the kinase activity of VRK1. A conventional in vitro kinase assay (IVK) of GST-VRK1 and DsRed1-VRK1 prepared
by immunoprecipitation using an anti-VRK1 antibody was performed with histone H3 as a substrate. GST-VRK1 employed in a pulldown assay
(pull down3IVK) was prepared as follows: GST-VRK1 was initially preincubated with total cell extracts overnight at 4°C and collected by affinity
pulldown (GPD) using glutathione beads. GST-VRK1 on beads was released by treatment with reduced glutathione. (E) Nucleoplasmic inhibition
of VRK1. An in vitro kinase assay of GST-VRK1 was carried out as described for panel D except with preincubation with extracts from cytoplasm
(cyto), nucleoplasm (nuc), and chromatin (chro).
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G1 to G2, which may represent an intermediate stage prior to
comprehensive condensation. Endogenous VRK1 was dissoci-
ated from chromatin during mitosis progression, and its ex-
pression decreased from the prometaphase to the anaphase
(Fig. 1F), whereas DsRed1-C1-VRK1 remained associated
with chromatin even at the anaphase (Fig. 7D). Therefore, the
phosphorylation of histone H3 by DsRed1-C1-VRK1 may
overwhelm the endogenous histone phosphatase activity, re-
sulting in hyperphosphorylation of histone H3 at Thr3 and
Ser10 and abnormal nuclear morphology. Immunostaining for
lamin B (Fig. 7E) revealed that nuclear hypercondensation
caused by DsRed1-C1-VRK1 triggered crushing of the nuclear
envelope. This finding is similar to previous data obtained from
immunostaining for NIMA kinase (28). Since VRK1 phosphor-
ylates p53 protein (27, 46), we tested whether this nuclear
condensation occurs in H1299 cells that do not express p53.
FIG. 7. Induction of nuclear condensation by DsRed1-C1-VRK1. (A and B) HeLa cells were transfected with control vector (DsRed1-C1),
DsRed1-C1-VRK1, or DsRed1-C1-VRK3 and then analyzed by microscopy after 24 h (A). The diameter of each nucleus measured as the long
axis was analyzed using Axiovision software (Carl Zeiss) (B). (C) Representative nuclear morphologies of DsRed1-C1-VRK1-expressing cells.
Condensed nuclei were composed of heterochromatinized foci (panel i; 31.2%), uniform comprehensive condensation (panel ii; 50.5%), and
partitioned comprehensive condensation (panel iii; 17.2%). (D) Chromatin localization and nuclear condensation during cell cycle in the cells
transfected with DsRed1-C1-VRK1. A combination of hydroxyurea and mimosine was used to arrest cells in G1 phase, and double thymidine
blocking and subsequent release for 1 h was used to obtain cells in early S or G2 phase. Mitotic cells were identified on the basis of the DNA
morphology. (E) Disorganization of the nuclear envelope induced by the presence of DsRed1-C1-VRK1. HeLa cells transfected with DsRed1-
C1-VRK1 were immunostained for lamin B (green) and DNA (Hoechst; blue). (F) Nuclear condensation of VRK1 in p53 null H1299 cells. The
three panels at the right show magnifications of the dotted square in the leftmost panel. (G) Apoptotic DNA fragmentation was determined by
TUNEL assays in the cells transfected with DsRed1-C1-VRK1 for the indicated durations. Scale bars represent 10 m in panel A, 5 m in panels
C, D, and H, and 20 m in panels E and F. DIC, differential interference contrast.
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Our data show that nuclear condensation caused by DsRed1-
C1-VRK1 is independent of the presence of p53 protein (Fig.
7F). In addition, we demonstrated that the DsRed1-C1-VRK1-
expressing cells were alive by showing negative staining for the
TUNEL assay (Fig. 7G); however, when expression continued
for a longer duration, approximately 30% of VRK1-expressing
cells gave positive results in the TUNEL assay (Fig. 7G). These
results imply that this nuclear condensation is not associated
with potential apoptosis events. To our knowledge, DsRed1-
C1-VRK1 is the first mammalian mitotic protein kinase that
induces nuclear condensation.
DISCUSSION
Chromatin-localized VRK1 as a histone kinase. VRK1
phosphorylates transcription factors, including p53 (27), c-Jun
(43), and ATF2 (44). These phosphorylation reactions pre-
dominantly occur in the nucleus. The cytosol contains several
structural and functional organelles, such as endoplasmic re-
ticulum, Golgi body, and lysosome. Notably, the nucleus also
contains subnuclear structures including nucleolus, promyelo-
cytic oncogenic domain, Cajal body, and histone deacetylase-
enriched foci as well as euchromatin and heterochromatin
regions (13). These subnuclear structures lack a membranous
barrier, which facilitates translocation among them. However,
the intrinsic functions of a nuclear protein are restricted by the
requirements of the exact subnuclear localization. The present
report shows that endogenous VRK1 localizes in the chroma-
tin and the nucleoplasm as well. First, biochemical analyses of
subnuclear distribution revealed significant levels of both en-
dogenous and transiently expressed ectopic VRK1 in chroma-
tin. Second, core histones, the fundamental components of
chromatin, were identified as binding partners of VRK1, while
there was no evident binding protein in nucleoplasm that in-
teracted with VRK1 during an in vitro binding assay. Third,
HP1, a well-characterized chromatin-localized protein, colo-
calized with VRK1. Moreover, BAF, a newly identified sub-
strate protein of VRK1, localizes in chromatin (33).
The chromatin localization of VRK1 indicates a role in the
phosphorylation of core histones, which are binding proteins in
the nucleus. In this report we show that VRK1 phosphorylates
histone H3 at two sites, Thr3 and Ser10, both in vitro and in
vivo. Earlier studies provide evidence that these sites are phos-
phorylated by haspin (Thr3) and aurora B (Ser10). The phos-
phorylation patterns of these two sites were similar with re-
spect to elapsed time. Specifically, phosphorylation become
apparent at early mitosis (from late G2 to prophase), peaked at
the metaphase, and disappeared at late mitosis (telophase).
Our results suggest that VRK1 plays an essential role in the
mitotic phase by phosphorylating Thr3 and Ser10 of histone
H3. Moreover, the contribution of VRK1 with respect to Ser10
phosphorylation was similar with aurora B. It is reported that
lack of histone H3 phosphorylation at Thr3 causes accumula-
tion of cells in prometaphase and leads to failure of metaphase
chromosome alignment (5). Inhibition of Ser10 phosphoryla-
tion by inactivating aurora B with hesperadin, an inhibitor, also
leads to improper attachment of kinetochore fibers to the
chromosome (24), changes in binding properties of chromatin
proteins such as HP1 (7, 17), and failure to recruit the con-
densin complex and mitotic spindle assembly (10). NHK-1, a
Drosophila homolog of VRK1, phosphorylates T119 in histone
H2A and plays an essential role in mitotic progression and in
the formation of chromosome architecture in meiosis (1, 4, 19).
Although the net level of phosphorylation of histone H2A by
VRK1 was weaker than that seen with H3 during in vitro
kinase assay (Fig. 4B), it is possible that VRK1 phosphorylates
T119 in H2A in vivo. Hence, future study on the relationship
between the distinct phosphorylation patterns of different hi-
stones will open the door to deciphering the histone code,
especially with respect to maintenance and the dynamics of
chromatin architecture. In accordance with these previous
studies, our results suggest that VRK1-mediated phosphoryla-
tion of Thr3 and Ser10 in histone H3 is functionally linked to
the formation of proper chromosome architecture.
Overexpression of DsRed1-C1-VRK1, the constitutively ac-
tive form of the kinase, induced marked nuclear condensation
in transfected cells regardless of the cell cycle stages, in simi-
larity to data obtained following ectopic expression of NIMA
in mammalian cells. The existence of a NIMA-like pathway in
mammalian cells has been proposed previously (28). Our data
provide evidence that the NIMA-like pathway in mammals is
mediated by VRK1. Transient expression of DsRed1-C1-
VRK1 caused hyperphosphorylation of Thr3 and Ser10 of hi-
stone H3, regardless of the cell cycle stage, and concomitantly
induced dramatic nuclear condensation, supporting the theory
that VRK1 is the mammalian functional counterpart of NIMA.
Another possibility is that VRK1 phosphorylates alternative
sites in histones or other target proteins that play critical roles
in chromatin condensation.
Cell cycle-regulated expression of VRK1. Recently, BAF was
revealed as a bona fide substrate of VRK1 (33). VRK1 phos-
phorylates BAF following a short incubation period during an
in vitro kinase assay. Subcellular localization of BAF is regu-
lated during cell cycle progression (42). During interphase,
BAF is present in the nucleus as a complex with chromatin
formed via direct interactions with DNA and with the nuclear
envelope via association with components of a nuclear lamin
complex such as LAP2, emerin, and MAN1. In contrast, BAF
localization becomes dynamic during mitotic progression.
From the metaphase to the anaphase, BAF is dissociated from
chromatin and localizes to the cytoplasm. In the telophase,
BAF relocalizes to chromatin. Such dynamic subcellular local-
ization of BAF is possibly regulated by its phosphorylation
status (2), which in turn is modulated by VRK1 (33). Our
present findings demonstrate that VRK1 expression and activ-
ity are regulated in a cell cycle-dependent manner. A gradual
increase in VRK1 expression was observed from the G1 to the
mitotic phase. Moreover, VRK1 activity correlated with ex-
pression. Thus, the expression and activity profiles of VRK1
may affect phosphorylation status and trigger dynamic local-
ization of BAF during the cell cycle.
Interestingly, expression of Flag-tagged VRK1 under con-
trol of the cytomegalovirus promoter was variable in trans-
fected cells, suggesting the existence of another mechanism to
regulate the amount of VRK1 protein. Protein degradation
mediated by APC/C (anaphase promoting complex-cyclosome)
is critical for modulating the amount of cell cycle regulators
and mitotic progression (35). APC/C is a major ubiquitin E3
enzyme responsible for the degradation of mitotic kinases,
including aurora A and B, Nek2A, and Plk1, via a proteasome-
8544 KANG ET AL. MOL. CELL. BIOL.
 o
n
 M
ay 7, 2015 by PO
STECH LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
dependent pathway (9, 35). The VRK1 protein level was also
altered during the cell cycle. Following nocodazole washout to
induce cell cycle progression, MG132 treatment blocked the
degradation of VRK1 and inhibited exit from the mitotic
phase, as evaluated by assays of the phospho-H3 S10 level (see
Fig. S3 in the supplemental material). Thus, while the nature
of the precise molecular mechanism involved in VRK1 degra-
dation awaits further investigation, regulation of VRK1 stabil-
ity by the proteasome is one of the potential mechanisms for its
expression profile during the cell cycle.
In summary, our results provide evidence for the function
and expression of chromatin-associated VRK1 and establish
the mitotic histone kinase activity profile during cell cycle pro-
gression. We propose that VRK1 phosphorylates core histones
mainly at the G2/M transition to trigger chromosome conden-
sation.
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